These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 9280671

  • 1. [Tacrine in Alzheimer's disease].
    López de Munain A.
    Rev Neurol; 1997 Jul; 25 Suppl 1():S70-2. PubMed ID: 9280671
    [No Abstract] [Full Text] [Related]

  • 2. Tacrine. Alzheimer's disease and the cholinergic theory. A critical review and results of a new therapy.
    Boller F, Orgogozo JM.
    Neurologia; 1995 May; 10(5):194-9. PubMed ID: 7619536
    [No Abstract] [Full Text] [Related]

  • 3. [Clinical study of patients with Alzheimer's disease under treatment with tacrine].
    García-López MT, Guardado-Santervás P.
    Rev Neurol; 1995 May; 32(4):394-7. PubMed ID: 11398762
    [No Abstract] [Full Text] [Related]

  • 4. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD.
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [Abstract] [Full Text] [Related]

  • 5. Alzheimer's disease: the role of tacrine therapy.
    Jogerst G.
    Iowa Med; 1995 Oct; 85(10):409-11. PubMed ID: 7591656
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacoepidemiology of tacrine in Alzheimer's disease.
    Begaud B, Haramburu F, Miremont G.
    Methods Find Exp Clin Pharmacol; 1996 Oct; 18 Suppl B():77-8. PubMed ID: 8899701
    [No Abstract] [Full Text] [Related]

  • 7. [Tacrine].
    Dávila C, Viteri C, de Castro P.
    Rev Med Univ Navarra; 1997 Oct; 41(1):58-64. PubMed ID: 9527715
    [Abstract] [Full Text] [Related]

  • 8. [Should Alzheimer disease be treated with tacrine? Review of the literature].
    Arsland D, Laake K.
    Tidsskr Nor Laegeforen; 1996 Sep 30; 116(23):2791-4. PubMed ID: 8928167
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Shao D, Zou C, Luo C, Tang X, Li Y.
    Bioorg Med Chem Lett; 2004 Sep 20; 14(18):4639-42. PubMed ID: 15324879
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity.
    Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB.
    Hepatology; 1996 Jun 20; 23(6):1429-35. PubMed ID: 8675160
    [Abstract] [Full Text] [Related]

  • 17. Alzheimer's disease: a new hope.
    Hasan MK, Mooney D.
    W V Med J; 1994 Oct 20; 90(10):418-9. PubMed ID: 7801627
    [Abstract] [Full Text] [Related]

  • 18. Cholinergic delirium and neurotoxicity associated with tacrine for Alzheimer's dementia.
    Trzepacz PT, Ho V, Mallavarapu H.
    Psychosomatics; 1996 Oct 20; 37(3):299-301. PubMed ID: 8849507
    [No Abstract] [Full Text] [Related]

  • 19. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy.
    Alhainen K, Riekkinen PJ.
    Acta Neurol Scand Suppl; 1993 Oct 20; 149():16-21. PubMed ID: 7907454
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer's disease agents.
    Chen Y, Sun J, Huang Z, Liao H, Peng S, Lehmann J, Zhang Y.
    Bioorg Med Chem; 2013 May 01; 21(9):2462-70. PubMed ID: 23541836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.